Advertisement

Inflammatory Bowel Disease Is Associated With an Increased Risk of Melanoma: A Systematic Review and Meta-analysis

      Background & Aims

      Inflammatory bowel disease (IBD) has been associated with an increased risk of nonmelanoma skin cancer, particularly among patients treated with thiopurines. It is unclear whether IBD affects risk for melanoma. We performed a systematic review and meta-analysis of cohort studies to determine the risk of melanoma in patients with IBD.

      Methods

      We conducted a systematic search of bibliographic databases through March 2013. Cohort studies reporting incident melanoma after IBD diagnosis and an estimate of incidence rate ratio or standardized incidence rate were included in the analysis. Pooled relative risk (RR) estimates with 95% confidence intervals (CIs) were calculated using the random-effects model.

      Results

      Our analysis included 12 studies, comprising a total of 172,837 patients with IBD; 179 cases of melanoma were reported from 1940 to 2009. The pooled crude incidence rate of melanoma in patients with IBD was 27.5 cases/100,000 person-years (95% CI, 19.9–37.0). Overall, IBD was associated with a 37% increase in risk of melanoma (12 studies: RR, 1.37; 95% CI, 1.10–1.70). The risk was increased among patients with Crohn’s disease (7 studies: RR, 1.80; 95% CI, 1.17–2.75) and ulcerative colitis (7 studies: RR, 1.23; 95% CI, 1.01–1.50). The risk of melanoma was higher in studies performed before introduction of biologic therapies (before 1998) (8 studies: RR, 1.52; 95% CI, 1.02–2.25) but not in studies performed after 1998 (2 studies: RR, 1.08; 95% CI, 0.59–1.96).

      Conclusions

      Based on a meta-analysis, IBD has been associated with an increased risk of melanoma, independent of the use of biologic therapy. Patients diagnosed with IBD should be counseled on their risk for melanoma.

      Keywords

      Abbreviations used in this paper:

      CD (Crohn's disease), CI (confidence interval), IBD (inflammatory bowel disease), IRR (incidence rate ratio), RR (relative risk), SIR (standardized incidence ratio), TNF (tumor necrosis factor), UC (ulcerative colitis)
      To read this article in full you will need to make a payment
      AGA Member Login
      Login with your AGA username and password.
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Purchase one-time access:

      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Simard E.P.
        • Ward E.M.
        • Siegel R.
        • et al.
        Cancers with increasing incidence trends in the United States: 1999 through 2008.
        CA Cancer J Clin. 2012; 62: 118-128
        • Psaty E.L.
        • Scope A.
        • Halpern A.C.
        • et al.
        Defining the patient at high risk for melanoma.
        Int J Dermatol. 2010; 49: 362-376
        • Long M.D.
        • Kappelman M.D.
        • Pipkin C.A.
        Nonmelanoma skin cancer in inflammatory bowel disease: a review.
        Inflamm Bowel Dis. 2011; 17: 1423-14237
        • Peyrin-Biroulet L.
        • Khosrotehrani K.
        • Carrat F.
        • et al.
        Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease.
        Gastroenterology. 2011; 141 (e1–5): 1621-1628
        • Yadav S.
        • Zinsmeister A.
        • Tremaine W.J.
        • et al.
        Cancer risk in a population-based cohort of infl ammatory bowel disease.
        Am J Gastroenterol. 2012; 107: S626
        • Bernstein C.N.
        • Blanchard J.F.
        • Kliewer E.
        • et al.
        Cancer risk in patients with inflammatory bowel disease: a population-based study.
        Cancer. 2001; 91: 854-862
        • Ekbom A.
        • Helmick C.
        • Zack M.
        • et al.
        Extracolonic malignancies in inflammatory bowel disease.
        Cancer. 1991; 67: 2015-2019
        • Long M.D.
        • Martin C.F.
        • Pipkin C.A.
        • et al.
        Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease.
        Gastroenterology. 2012; 143 (e1): 390-399
        • Wolfe F.
        • Michaud K.
        Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study.
        Arthritis Rheum. 2007; 56: 2886-2895
        • Burmester G.R.
        • Panaccione R.
        • Gordon K.B.
        • et al.
        Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease.
        Ann Rheum Dis. 2013; 72: 517-524
        • Lopez-Olivo M.A.
        • Tayar J.H.
        • Martinez-Lopez J.A.
        • et al.
        Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis.
        JAMA. 2012; 308: 898-908
        • Peyrin-Biroulet L.
        • Chevaux J.B.
        • Bouvier A.M.
        • et al.
        Risk of melanoma in patients who receive thiopurines for inflammatory bowel disease is not increased.
        Am J Gastroenterol. 2012; 107: 1443-1444
      1. Higgins J.P.T. Green S. Cochrane handbook for systematic reviews of interventions, version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 (Available at:)
        • Kanwal F.
        • White D.
        Systematic reviews and meta-analyses.
        Clin Gastroenterol Hepatol. 2012; 10: 1184-1186
        • Stroup D.F.
        • Berlin J.A.
        • Morton S.C.
        • et al.
        Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group.
        JAMA. 2000; 283: 2008-2012
      2. Wells GA, O’Connell D, Peterson J, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available at: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed December 15, 2012.

        • DerSimonian R.
        • Laird N.
        Meta-analysis in clinical trials.
        Control Clin Trials. 1986; 7: 177-188
        • Higgins J.P.
        • Thompson S.G.
        • Deeks J.J.
        • et al.
        Measuring inconsistency in meta-analyses.
        BMJ. 2003; 327: 557-560
        • Thompson S.G.
        • Pocock S.J.
        Can meta-analyses be trusted?.
        Lancet. 1991; 338: 1127-1130
        • Guyatt G.H.
        • Oxman A.D.
        • Kunz R.
        • et al.
        GRADE guidelines: 7. Rating the quality of evidence–inconsistency.
        J Clin Epidemiol. 2011; 64: 1294-1302
        • Egger M.
        • Davey Smith G.
        • Schneider M.
        • et al.
        Bias in meta-analysis detected by a simple, graphical test.
        BMJ. 1997; 315: 629-634
        • Easterbrook P.J.
        • Berlin J.A.
        • Gopalan R.
        • et al.
        Publication bias in clinical research.
        Lancet. 1991; 337: 867-872
        • Greenstein A.J.
        • Gennuso R.
        • Sachar D.B.
        • et al.
        Extraintestinal cancers in inflammatory bowel disease.
        Cancer. 1985; 56: 2914-2921
        • Hemminki K.
        • Li X.
        • Sundquist J.
        • et al.
        Cancer risks in Crohn disease patients.
        Ann Oncol. 2009; 20: 574-580
        • Jess T.
        • Winther K.V.
        • Munkholm P.
        • et al.
        Intestinal and extra-intestinal cancer in Crohn's disease: follow-up of a population-based cohort in Copenhagen County, Denmark.
        Aliment Pharmacol Ther. 2004; 19: 287-293
        • Karlen P.
        • Lofberg R.
        • Brostrom O.
        • et al.
        Increased risk of cancer in ulcerative colitis: a population-based cohort study.
        Am J Gastroenterol. 1999; 94: 1047-1052
        • Mellemkjaer L.
        • Olsen J.H.
        • Frisch M.
        • et al.
        Cancer in patients with ulcerative colitis.
        Int J Cancer. 1995; 60: 330-333
        • Persson P.G.
        • Karlen P.
        • Bernell O.
        • et al.
        Crohn's disease and cancer: a population-based cohort study.
        Gastroenterology. 1994; 107: 1675-1679
        • Winther K.V.
        • Jess T.
        • Langholz E.
        • et al.
        Long-term risk of cancer in ulcerative colitis: a population-based cohort study from Copenhagen County.
        Clin Gastroenterol Hepatol. 2004; 2: 1088-1095
        • Setshedi M.
        • Epstein D.
        • Winter T.A.
        • et al.
        Use of thiopurines in the treatment of inflammatory bowel disease is associated with an increased risk of non-melanoma skin cancer in an at-risk population: a cohort study.
        J Gastroenterol Hepatol. 2012; 27: 385-389
        • Breslow A.
        Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma.
        Ann Surg. 1970; 172: 902-908
        • Balch C.M.
        • Gershenwald J.E.
        • Soong S.J.
        • et al.
        Final version of 2009 AJCC melanoma staging and classification.
        J Clin Oncol. 2009; 27: 6199-6206
        • Howlader N.
        • Krapcho M.
        • Neyman N.
        • et al.
        SEER cancer statistics review, 1975-2009.
        National Cancer Institute, Bethesda, MD2011
        • Kubica A.W.
        • Brewer J.D.
        Melanoma in immunosuppressed patients.
        Mayo Clin Proc. 2012; 87: 991-1003
        • Le Mire L.
        • Hollowood K.
        • Gray D.
        • et al.
        Melanomas in renal transplant recipients.
        Br J Dermatol. 2006; 154: 472-477
        • Szepietowski J.
        • Wasik F.
        • Szepietowski T.
        • et al.
        Excess benign melanocytic naevi in renal transplant recipients.
        Dermatology. 1997; 194: 17-19
        • Greene M.H.
        • Young T.I.
        • Clark Jr., W.H.
        Malignant melanoma in renal-transplant recipients.
        Lancet. 1981; 1: 1196-1199
        • Dillon P.
        • Thomas N.
        • Sharpless N.
        • et al.
        Regression of advanced melanoma upon withdrawal of immunosuppression: case series and literature review.
        Med Oncol. 2010; 27: 1127-1132
        • Guenova E.
        • Lichte V.
        • Hoetzenecker W.
        • et al.
        Nodular malignant melanoma and multiple cutaneous neoplasms under immunosuppression with azathioprine.
        Melanoma Res. 2009; 19: 271-273
        • Pedersen N.
        • Duricova D.
        • Elkjaer M.
        • et al.
        Risk of extra-intestinal cancer in inflammatory bowel disease: meta-analysis of population-based cohort studies.
        Am J Gastroenterol. 2010; 105: 1480-1487